ᱩᱛᱱᱟ.ᱣ
ᱡᱤᱱᱤᱥ ᱠᱚ: ᱠᱟᱨᱟᱢᱮᱞ ᱠᱚ
ᱢᱮᱥᱮᱡᱽ/ᱢᱤᱴᱚᱨ: ᱠᱭᱩᱵᱤᱠ, ᱑᱐%
ᱠᱚᱯᱤᱨᱟᱭᱤᱴ: ᱯᱮᱭᱢᱮᱱᱴᱥ, ᱯᱮᱭᱰ ᱵᱮᱝᱠ, ᱯᱤᱥᱤ-᱔, ᱵᱮᱵᱥᱟ, ᱵᱮᱵᱥᱟ, ᱵᱮᱵᱥᱟ, ᱵᱮᱵᱥᱟ, ᱵᱮᱵᱥᱟ, ᱵᱮᱵᱥᱟ
᱐᱐᱐/᱑᱐:᱐᱐: ᱰᱨᱟᱢᱟ ᱰᱤᱞᱟᱨᱥᱤᱯ |
ᱰᱮᱞᱤᱵᱷᱟᱨ: ᱯᱮᱢᱮᱱᱴ ᱛᱟᱭᱚᱢ ᱢᱩᱪᱟᱹᱫᱚᱜ ᱞᱟᱦᱟᱨᱮ
ᱮᱢᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢᱮᱢ: ᱓᱕᱐ ᱢᱤᱢᱤᱢ/ᱢᱤᱴᱚᱨ, ᱮᱢᱮᱢᱡᱤ/ᱮᱢᱮᱢ, ᱓᱕᱐ ᱢᱤᱢᱤᱢ, ᱮᱢ/ᱮᱢ,
ᱯᱷᱟᱨᱢᱟᱥᱭᱩᱴᱤᱠᱟᱞ ᱟᱨ ᱯᱷᱟᱨᱢᱟᱥᱭᱩᱴᱤᱠᱟᱞ ᱥᱠᱮᱞ
ᱡᱤᱱᱤᱥ ᱠᱚ: ᱠᱟᱨᱰᱤᱭᱟᱠ ᱡᱤᱱᱤᱥ
ᱯᱷᱟᱨᱢᱟᱠᱳᱞᱳᱡᱤ ᱮᱥᱮᱨ ᱠᱚᱺ
11. ᱜᱞᱩᱠᱚᱡᱽ-ᱯᱨᱚᱰᱟᱠᱴ ᱜᱞᱩᱠᱚᱡᱽ: ᱨᱟᱱᱠᱚ ᱨᱮᱭᱟᱜ ᱜᱞᱩᱠᱚᱡᱽ, ᱮᱱᱡᱟᱭᱤᱢ, ᱟᱨ ᱮᱱᱡᱟᱭᱤᱢ ᱠᱚ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ ᱠᱚ ᱨᱮ ᱮᱥᱮᱨᱟ᱾
23. gmphogenes of group kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ lạṛhi kạmi lạṭ ᱠᱟᱱᱟ ᱠᱚ, ᱟᱨ ᱠᱚᱢ ᱠᱚ ᱠᱚᱢ ᱫᱟᱲᱮᱭᱟᱜ ᱠᱟᱱᱟ᱾
ᱯᱨᱚᱰᱟᱠᱴᱤᱵᱷᱤᱴᱤ
1.Dual mechanism: A unique compound formula that combines the effects of GLP-1 receptor agonists and SGLT-2 inhibitors to synergistically lower blood sugar and reduce weight.
2. 1. 3. 1. ᱱᱤᱭᱩᱠᱞᱤᱭᱟᱨ ᱜᱞᱩᱠᱚᱡᱽ (GFP) ᱫᱚ ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱡᱤᱱᱤᱥ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱵᱟᱝ ᱵᱟᱰᱟᱭ ᱧᱟᱢ ᱟᱠᱟᱱᱟ ᱡᱮ ᱱᱚᱶᱟ ᱠᱚ ᱫᱚ ᱟᱹᱰᱤ ᱵᱟᱹᱲᱛᱤ ᱯᱨᱚᱴᱤᱱ ᱠᱚ ᱦᱩᱭᱩᱜ-ᱟ ᱾
3. ᱠᱟᱨᱰᱤᱭᱟᱠ ᱨᱟᱱ ᱠᱚ ᱨᱮᱭᱟᱜ ᱚᱨᱡᱚ ᱫᱚ ᱦᱩᱭᱩᱜ ᱠᱟᱱᱟ: ᱢᱟᱨᱟᱝ ᱠᱟᱨᱰᱤᱭᱚᱵᱟᱥᱠᱩᱞᱟᱨ ᱨᱚᱜᱽ ᱨᱮᱭᱟᱜ ᱚᱨᱡᱚ ᱫᱚ ᱠᱚᱢᱡᱩᱨᱤ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ ᱠᱟᱱᱟ᱾
4. ᱦᱟᱭᱵᱽᱨᱤᱰᱟᱭᱡᱮᱥᱚᱱ: ᱜᱮᱥᱴᱨᱤᱠ ᱠᱮᱱᱥᱟᱨ ᱟᱨ ᱠᱚᱢᱯᱨᱮᱥᱚᱨ ᱨᱮᱭᱟᱜ ᱞᱚᱞᱚ ᱵᱟᱹᱲᱛᱤ ᱞᱟᱹᱜᱤᱫ ᱾
ᱦᱚᱜᱽᱥ: ᱢᱟᱨᱟᱝ ᱢᱚᱰᱮᱞ ᱠᱚ ᱫᱚ 55 kg 25 kg khabooks, hapoption generype, hipoption, hodiabode khon jạruṛ ge khabox hable khabution, hapap hapababox lạgit̕ jạruṛ ge kạmi khon khabodabode ke ko keabooke kebource app hable ko a g kg .